Disease Burden, Treatment Patterns, and Economic Impact of Rectovaginal Fistulas in Patients with Crohn’s Disease: Findings from a Retrospective, Observational, Longitudinal Study Based on US Claims Databases

Chitra Karki (), Dominick Latremouille-Viau, Inmaculada Gilaberte, Gary Hantsbarger, Hela Romdhani and Amy L. Lightner ()
Additional contact information
Chitra Karki: Takeda Pharmaceuticals USA, Inc.
Dominick Latremouille-Viau: Analysis Group, Inc.
Inmaculada Gilaberte: Tres Cantos
Gary Hantsbarger: Takeda Pharmaceuticals USA, Inc.
Hela Romdhani: Analysis Group, Inc.
Amy L. Lightner: Cleveland Clinic

PharmacoEconomics - Open, 2023, vol. 7, issue 5, No 9, 822 pages

Abstract: Abstract Background Crohn’s-related rectovaginal fistulas (RVF) greatly impact quality of life and are notoriously difficult to treat. The aim of this study was to assess the burden of recurrent episodes of care for RVF and its economic impact. Methods A retrospective observational cohort study of administrative US claims databases was conducted. Eligible patients were female adults, with a diagnosis code for Crohn’s disease with or without a diagnosis/procedural code for RVF. For the RVF cohort, rates of recurrence of RVF episodes of care were estimated using Kaplan–Meier analyses. Healthcare resource utilization (HCRU) and direct healthcare costs were compared between the RVF cohort and RVF-free cohort. Results Mean ages in the RVF cohort (n = 963) and RVF-free cohort (n = 56,564) were 47.2 and 50.8 years, with a mean follow-up period of 58.7 and 49.8 months, respectively. For the RVF cohort, the probability of having a second RVF episode of care within 2 years of the first one was estimated to be 35.9% and of having a third episode within 2 years of the second was 47.8%. During the first 2 years, the RVF cohort had 67% more inpatient admissions than the RVF-free cohort with each RVF episode of care being associated with 16% more admissions. The estimated incremental cost associated with having RVF was US$17,561, with an incremental cost of US$11,607 for each additional RVF episode of care. Conclusions This real-world study highlights the significant impact of RVF in patients with Crohn’s disease with regard to repeat interventions and associated HCRU and direct healthcare costs, suggesting novel therapeutics are needed in this patient population.

Date: 2023
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-023-00424-z Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:7:y:2023:i:5:d:10.1007_s41669-023-00424-z

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-023-00424-z

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().